[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647703":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":18,"responsibleParty":38,"collaborators":18,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":18,"enrollmentInfo":51,"targetDuration":18,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":18,"overallStatus":60,"whyStopped":18,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":18},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cell Saver","ACTIVE_COMPARATOR","Randomized to utilize cell savor intraoperatively",[13],"Device: Cell Saver",{"label":15,"type":16,"description":17,"interventionNames":18},"No Cell Saver","NO_INTERVENTION","Control Arm",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":18},"DEVICE","Using Cell Saver during surgery",[9],[25],{"name":26,"affiliation":5,"role":27},"Anthony Mikula, M.D.","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":18,"email":33},"Laura Westendorf","CONTACT","507-284-8167","westendorf.laura@mayo.edu",{"name":35,"role":31,"phone":36,"phoneExt":18,"email":37},"Justice Story","507-422-5528","story.justice@mayo.edu",{"type":27,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Anthony L. Mikula","Senior Associate Consultant, Neurosurgery","100647703","salvage-trial-safety-and-clinical-value-of-autologous-reinfusion-100647703",false,"NCT07712666","SALVAGE Trial (Safety And cLinical Value of AutoloGous rEinfusion)","SALVAGE Trial (Safety And cLinical Value of AutoloGous rEinfusion): A Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing Intraoperative Cell Salvage Versus No Cell Salvage in Adult Spinal Deformity Surgery","SALVAGE","Inclusion Criteria:\n\n* Patients \\>18 years of age undergoing adult thoracolumbar spinal deformity surgery as defined by one or more of the following radiographic criteria: 1) sagittal vertical axis \\> 15 cm, pelvic incidence (PI) minus lumbar lordosis (LL) \\> 25°, T1 pelvic angle \\> 30°, thoracic scoliosis \\> 70°, thoracolumbar\u002Flumbar scoliosis \\> 50°, or global coronal alignment \\> 7 cm; 2) one or more of the following surgical criteria: posterior spinal fusion \\> 12 levels, 3-column osteotomy (3CO), or anterior-column reconstruction; or 3) age \\> 65 years and undergoing a minimum of 7 levels of spinal instrumentation surgery (geriatric criteria).\n\nExclusion Criteria:\n\n* Patients with active spinal infection, neoplasm, acute trauma, neuromuscular etiology, syndromic scoliosis, prisoners, and pregnant patients","ALL","18 Years",{"count":52,"type":53},146,"ESTIMATED","INTERVENTIONAL",[56],"NA","The investigator hypothesizes intraoperative salvaged red blood cells are a poor substitute for allogenic packed red blood cell transfusions. In addition to providing inadequate resuscitation, salvaged red blood cells can increase the rate of complications, including postoperative electrolyte abnormalities, thrombocytopenia, anemia, and coagulopathy.",[59],"Adult Spinal Deformity Surgery","NOT_YET_RECRUITING","2026-07-14",{"date":63,"type":64},"2026-07-17","ACTUAL",{"date":66,"type":53},"2026-08-01",{"date":68,"type":53},"2029-08-01",{"name":5,"class":6}]